Benzinga | Apr 29, 2021 07:58AM EDT

Phio Pharmaceuticals Announces Upcoming Data Presentations At ASGCT And ASCO Annual Meetings

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL(tm)) therapeutic platform, today announced new data to be presented at the upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), which is being held on May 11 - May 14, 2021, and the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held on June 4 - 8, 2021.

Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

Details are as follows:

Event: 24th Annual Meeting of the ASGCT

Poster INTASYL PH-762 Self-Delivering RNAi Targeting PD-1 Enhances theTitle: Therapeutic Efficacy of Systemically Administered HER2-Targeted CAR-T Cells in a SKOV3 Model of Human Ovarian Adenocarcinoma in NCG Mice

Authors: Benjamin Cuiffo, et al.

Abstract 431Number:

Date/ 8:00 AM - 10:00 AM on Tuesday, May 11, 2021Time:

Event: The 2021 ASCO Annual Meeting

Poster INTASYL Self-Delivering RNAi Therapy Specifically Dual-Targeting BRD4Title: and PD-1 Elicits Complete Tumor Responses and Evidence of Synergy in a Subcutaneous Hepa1-6 Model of Murine Hepatoma in C57BL/6N Mice

Authors: Benjamin Cuiffo, et al.

Abstract e14537Number:

Date: Friday, June 4, 2021



Archived versions of the Phio presentations will be made available on the "Investors -- Events and Presentations" section of the Company's website (click here).